Antitumor Virotherapy by Attenuated Measles Virus (MV)

Biology

Jean-Baptiste Guillerme¹  Marc Gregoire¹  Frຝéric Tangy² 

[1] INSERM, UMR892, Nantes, F-44000, France; E-Mails:;CNRS, URA3015, Institut Pasteur, Unité de Génomique Virale et Vaccination, Paris, 75015, France; E-Mail:

关键词: antitumor virotherapy;    measles virus vaccine;    dendritic cells;    tumor antigen;    clinical trial;    vaccine;   

DOI  :  10.3390/biology2020587

来源: mdpi

【 摘 要 】

Antitumor virotherapy consists of the use of replication-competent viruses to infect and kill tumor cells preferentially, without damaging healthy cells. Vaccine-attenuated strains of measles virus (MV) are good candidates for this approach. Attenuated MV uses the CD46 molecule as a major entry receptor into cells. This molecule negatively regulates the complement system and is frequently overexpressed by cancer cells to escape lysis by the complement system. MV exhibits oncolytic properties in many cancer types in vitro, and in mouse models. Phase I clinical trials using MV are currently underway. Here, we review the state of this therapeutic approach, with a focus on the effects of MV on the antitumor immune response.

【 授权许可】

CC BY   
© 2013 by the authors; licensee MDPI, Basel, Switzerland.